Preprint
Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy
Abstract
Purpose
Chimeric antigen receptor T-cell (CART) therapy has shown clinical efficacy in refractory and relapsed large B-cell lymphomas, but is associated with serious acute and long-term toxicities. To understand the patient perspective, we measured a patient-reported outcome (PRO), specifically, health-related quality of life (HRQoL), at multiple time points over one year.
Authors
Balitsky A; Pond G; Davies G; Fraser G; Kouroukis T; Levine M; Meyer R; Foley R
DOI
10.21203/rs.3.rs-2907146/v1
Preprint server
Research Square